Summary:
We determined the safety, immune activating effects, and potential efficacy of i.v. infusion of ex vivo interleukin-2 (IL-2) activated natural killer (NK) cells (part I) or IL-2 boluses (part II) during daily s.c. IL-2 administration following hematopoietic recovery from autologous transplantation. In all, 57 patients with relapsed lymphoma (n ¼ 29) or metastatic breast cancer (n ¼ 28) were enrolled. In part I of the study, 34 patients were enrolled at three dose levels of ex vivo IL-2-activated NK cells. Lymphaphereses were performed on days 28 and 42 of s.c. IL-2 administration. Following overnight ex vivo IL-2 activation of the pheresis product, the cells were reinfused the following day. In part II, 23 patients were enrolled at three dose levels of supplemental i.v. IL-2 bolus infusions, given on days 28 and 35 during s.c. IL-2 administration. Toxicities were generally mild, and no patient required hospitalization. Lytic function was markedly enhanced for fresh peripheral blood mononuclear cells (PBMNCs) obtained 1 day postinfusion of either IL-2-activated cells or IL-2 boluses. IL-2 boluses transiently increased the levels of IL-6, IFN-c, TNF-a and IL1-b, with increases in IL-6 and IFN-c being dose dependent. A total of 37 patients (19 patients with lymphoma, 18 with breast cancer) treated with an optimum dose of post-transplant immunotherapy (defined as having received 1.75 Â 10 6 IU/ m 2 /day of s.c. IL-2 plus at least one of the planned ex vivo IL-2-activated cell infusions/IL-2 boluses) could be matched with controls from the Autologous Blood and Marrow Transplant Registry database. The matchedpairs analysis demonstrated no improvement in disease outcomes of survival and relapse. We conclude that IL-2-activated cells/IL-2 boluses can be safely administered, generate PBMNCs with enhanced cytotoxicity against NK-resistant targets, and increase cytokine levels. With this dose and schedule of administration of IL-2, no improvement in patient disease outcomes was noted. High-dose chemotherapy with autologous stem cell support has been widely employed in the treatment for relapsed lymphoma and metastatic breast cancer. In chemotherapysensitive lymphoma and metastatic breast cancer patients, autologous transplantation can result in high remission rates.
1,2 However, many patients who achieve a complete remission following transplantation will relapse and die of their disease. Most patients relapse at sites of previous bulk disease, suggesting that one reason for treatment failure is inability to eradicate chemotherapy-resistant clonogenic tumor. An inadequately functioning immune system may also contribute to early relapse.
Human natural killer (NK) cells represent a population of large granular lymphocytes that express the CD56+/ CD3À phenotype. Recombinant interleukin-2 (IL-2) stimulates both NK expansion and cytotoxic activity against tumor targets in vivo and in vitro, including lymphoma and breast cancer. 3, 4 Theoretically, IL-2-activated NK cells, functioning as short-term antitumor therapy, would be most efficacious in a minimal residual disease setting such as that induced by autologous transplantation. Following initial reports of the feasibility and immunologic potential of post-transplant IL-2 immunotherapy, 5-7 many investigators explored IL-2 and/or IL-2-activated effectors for a variety of malignancies with encouraging but inconclusive results. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] We previously reported the results of a phase I trial of post-autologous transplant s.c. IL-2 (Amgen Inc., Thousand Oaks, CA, USA). 4 In all, 12 patients (six lymphoma, six breast cancer) were enrolled on a dose-escalation study of s.c. IL-2 given for 84 days; the best-tolerated dose was 0.25 Â 10 6 U/m 2 /day. Patients receiving at least 28 days of s.c. IL-2 exhibited a greater than 10-fold increment in circulating NK cells. In addition, lytic function was increased against the NK-resistant targets Raji (lymphoma) and MCF-7 (breast cancer). In vivo IL-2-primed NK cells obtained by lymphapheresis were activated in large-scale ex vivo incubation in high-dose IL-2 (1000 U/ml), with further enhancement of NK lytic function against Raji and MCF-7 targets. We concluded that low-dose s.c. IL-2, although safe and easily administered in the outpatient setting, resulted in submaximal NK lytic function against tumor targets, and hypothesized that ex vivo incubation in IL-2 could be used to generate NK cells with potent antitumor effects. In the current study, we sought to extend these observations by performing a phase I/II trial of infusion of ex vivo IL-2-activated NK cells to determine if this strategy would generate NK cells with sustained and potent antitumor effects. We subsequently evaluated whether i.v. boluses of IL-2 could be substituted for the ex vivo IL-2-activated cell infusions, while maintaining the same degree of immune activation.
Patients and methods

Patient characteristics and eligibility criteria
In all, 34 patients between 18 and 65 years of age who had undergone an autologous stem cell transplant for nonHodgkin's lymphoma, Hodgkin's disease, or metastatic breast cancer with no evidence of disease progression were enrolled on the ex vivo IL-2 activation part of the study (Table 1) . A total of 23 additional patients were enrolled on the IL-2 bolus part of the study. Patients with T-cell immunophenotype non-Hodgkin's disease were not eligible. Conditioning regimens were as previously described. 1, 28 Patients had to be between 30 and 180 days from transplant, transfusion independent, without need for growth factor support, and have an unsupported platelet count X80 000 Â 10 9 /l, hemoglobin X9 gm/dl, and an ANC X1.0 Â 10 9 /l. The protocol received institutional review board approval and all patients exercised written informed consent when eligible for IL-2 therapy. Of the 28 patients with breast cancer, 18 (64%) also received s.c. IL-2 as part of pretransplant stem cell mobilization as previously described. 28 
s.c. IL-2 therapy
Amgen IL-2 had been used in our previous phase I trial of s.c. IL-2. 4 As Amgen IL-2 was no longer available, IL-2 was provided and manufactured by Chiron (Emeryville, CA, USA) for the current study. Hence, it was necessary to first establish the maximum tolerated dose (MTD) of Chiron-IL-2. Acetaminophen 650 mg, ibuprofen 400 mg, and diphenhydramine 50 mg were self-administered as oral premedications to IL-2, and repeated 4 h following each self-injection. In part I of the study, IL-2 doses of 0.25, 0.75, 1.25, 1.75, and 2.25 Â 10 6 IU/m 2 /day for 56 days were tested, within a range of Chiron IL-2 previously reported to expand NK cells in vivo without significant toxicity. 29 Patients were enrolled in cohorts of 3. Patients were not enrolled to the next dose level until a minimum of two patients had completed therapy at an IL-2 dose level with no dose limiting toxicity (DLT) attributable to IL-2 administration. DLT was defined by the Cancer and Leukemia Group B (CALGB) expanded common toxicity criteria as Grade 3 toxicity. Toxicity was first formally assessed at day 14 of IL-2 therapy, then every 14 days until 7-14 days after IL-2 was stopped. If no DLT had occurred by day 14, the patient could escalate to the next dose level for the duration of therapy. IL-2 was discontinued in patients experiencing DLT, then restarted at the next lower dose level once toxicity had resolved. The MTD of IL-2 was defined as the dose below that in which 33% of patients experienced DLT. The MTD was used as the daily s.c. dose of IL-2, administered for 42 days, in part II of the study.
Lymphapheresis and ex vivo IL-2 activation (part I)
Minimal laboratory values required prior to lymphapheresis included platelets 450 000 Â 10 9 /l, hemoglobin X9 gm/ dl, ANC X1.0 Â 10 9 /l, and normal renal and liver functions. Prior to the first lymphapheresis (day 28 of IL-2 therapy), patients must have received IL-2 for at least 21 of the first 28 days and for five of the 7 days immediately prior to the planned apheresis. Prior to the second lymphapheresis (day 42), patients must have received IL-2 for at least 28 of the first 42 days and five of the 7 days immediately prior to apheresis. Patients not meeting the criteria for apheresis continued on s.c. IL-2 alone. A volume of 10-12 l leukaphereses were performed using a CS3000 cell sorter (Baxter, Deerfield, IL, USA). The lymphapheresis product was cultured in AIM-V serum-free medium (Gibco) supplemented with 1000 IU/ml IL-2 in polyolefin gas permeable bags (Lifecell Tissue Culture Flask, Fenwal-Baxter) for 16 h, a time period previously shown to result in sustained induction of cytolytic activity against MCF-7 and Raji cell targets. 4 All patients received premedications 1 h prior to cell infusion and again 3-4 h later. IL-2-activated lymphocytes were infused over 1-2 h through a 170 mm blood administration filter the day following apheresis (days 29 and 43) in the outpatient clinic. Cell doses were based on mononuclear cells with the total cell count determined just prior to infusion. Patients were enrolled in cohorts of 3 patients each with dose escalation to a maximum of a full lymphapheresis product. Cohort 1 received 4.0 Â 10 7 cells/kg and cohort 2 received /day, all patients received the lowest cell dose of 4.0 Â 10 7 cells/kg. Cell dose escalation then proceeded only after all patients at a given dose were evaluated through day 56 of therapy (the last day of s.c. IL-2) with no DLT attributable to administration of IL-2 or IL-2-activated lymphocytes. Patients received the infusions on an outpatient basis and were observed for toxicity for a minimum of 4 h following infusion. Patients were formally assessed for toxicity the day prior to apheresis, during and following infusion of activated cells, and the day after cell infusion. DLT was defined as Grade 2 or greater toxicity by CALGB criteria except for the following where Grade 3 toxicity was dose limiting: liver, neurologic, hematologic, infection, pulmonary, dermatologic, allergy, performance status. A platelet count of o30 000 Â 10 9 /l was considered dose-limiting. After the MTD of IL-2 in combination with a full lymphapheresis was shown to be safe, accrual was extended to both ascertain safety and until part II of the study utilizing bolus IL-2 infusions could be initiated.
i.v. bolus IL-2 (part II)
The eligibility requirements for part II of the study were identical to part I of the study. All patients initiated s.c. IL-2 at the MTD established in part I of the study of 1.75 Â 10 6 IU/m 2 /day. If no DLT had occurred after 14 days, the patient continued at that dose for a total of 42 days of therapy. Patients who developed intolerable constitutional symptoms that did not constitute DLT decreased their IL-2 dose to 1.25 Â 10 6 IU/m 2 /day for the remainder of the study. Patients received the same pre-and post-medications for IV boluses of IL-2 as for the infusions of IL-2-activated cells. The IL-2 boluses were given as an outpatient over 2 h on days 28 and 35, with dose escalation per cohort of three patients each of 2.0, 4.0, and 6.0 Â 10 6 IU/m 2 per infusion. The dose of bolus IL-2 was not escalated until all patients in a given cohort had completed the entire course of IL-2 therapy. Hence, more than three patients were ultimately enrolled in the second and third cohorts. Prior to receiving bolus IL-2, patients must have received IL-2 for at least 21 of the first 28 days and for five of 7 days immediately prior to the planned infusion. Patients not meeting these criteria continued on daily s.c. IL-2 alone. The IL-2 was infused over 2 h on an outpatient basis and patients were monitored for a minimum of 4 h for complications. Patients were formally assessed for toxicity the day prior to the IL-2 bolus infusion, during and following the infusion and the day after infusion. The definition of DLT for bolus IL-2 was the same as for ex vivo IL-2-activated cell infusions.
Cytolytic activity
Heparinized peripheral blood, serum, and plasma were obtained at each clinic visit. Peripheral blood mononuclear cells (PBMNCs) were prepared from peripheral blood by Ficoll-Hypaque (sp. grav. 1.077) (Sigma, St Louis, MO, USA) density gradient centrifugation as described. 4 Cell surface antigens were determined by direct staining of cells with mouse monoclonal antibodies. Fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-coupled antibodies (Becton Dickinson, Mountain View, CA, USA) were directed at CD3, CD25, CD56, and HLA-DR. FITCand PE-coupled isotype-matched immunoglobulins were used as controls. All analyses were performed with FACSCalibur (Becton Dickenson) and CELLQuest software (Becton Dickenson). Cytotoxicity assays were performed in triplicate using fresh PBMNC or 16 h IL-2-activated PBMNC against the NK-resistant B-cell lymphoma line Raji (American Tissue Culture Collection (ATCC), Rockville) and the breast cancer cell line MCF-7 (ATCC) in a 4-hour 51 Cr release assay. 4 To control for target variability, frozen targets (expanded from the same batch) were thawed every 4-6 weeks.
Cytokine levels
Serum or plasma was stored at À701C and later assayed for cytokine levels using ELISA kits for interleukin-1b (IL-1b), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g). Assays were performed using the manufacturer's recommendations (R&D Systems, Minneapolis, MN, USA). Normal cytokine values for 495% of healthy individuals are considered by the University of Minnesota Cytokine Reference Laboratory to be as follows: IL-1b (o0.9 pg/ml), IL-6 (o3.0 pg/ml), TNF-a (o3.0 pg/ml), and IFN-g (o3.0 pg/ml).
Statistics
Results of experimental points were reported as mean7 standard error of the mean (s.e.m.). Statistical comparisons of experimental points between independent groups were completed with the two-sided Student's t-test. Comparisons of values at different time points but within the same population were made with a two-sided paired-comparison t-test. 30 Patients enrolled at the MTD of s.c. IL-2 and who received at least one of the planned ex vivo IL-2-activated cell infusions or IL-2 boluses (20 patients with lymphoma, 20 with breast cancer) were eligible to be matched to a maximum of three controls from the Autologous Blood and Marrow Transplant Registry (ABMTR) database. Controls were selected from 1726 potentially eligible patients from the database who had received an autologous transplant for lymphoma or breast cancer, had not received any post-transplant immunotherapy, were not transplanted at one of the study institutions, and had similar follow-up time. IL-2-treated patients were matched to controls for the following variables: disease (NHL, HD, metastatic breast cancer), histologic subtype at diagnosis or those patients with NHL or HD (Working Formulation subtype for NHL, nodular sclerosis/mixed cellularity/unknown for HD), disease status at time of transplant (primary induction failure with chemosensitive disease, clinical remission, or chemosensitive/resistant relapse for lymphoma; clinical remission, clinical remission except for bone abnormalities, or chemosensitive relapse for breast cancer), year of transplant (within 5 years), age at transplant (within 10 years), and time from diagnosis to transplant (within1.5 years). Patients with breast cancer were also matched to controls for the presence of visceral metastases and hormone receptor status. The case cohort included only patients who were in remission long enough to receive the IL-2 therapy after autologous transplantation, whereas the control cohort included all similar patients who were not treated with IL-2 therapy after autologous transplantation from the ABMTR. The IL-2-treated case cohort therefore excluded patients who died early or had an early relapse. This could introduce a bias favoring IL-2-treated cases. To adjust this potential waiting time bias, the controls in each match pair were selected from among the patients with a complete remission after transplantation at least as long as the interval between the transplantation and initial IL-2 therapy for the IL-2 recipient. If more than three controls were eligible for matching with an IL-2-treated patient, then the three controls closest in age to the case patient were chosen. Cox's regression model stratified on each matched pair was used to analyze the effect of IL-2 therapy on the end points of survival and relapse. The proportionality assumption of the Cox model was tested by adding a time-dependent covariate.
Results
Clinical tolerability of subcutaneous IL-2 therapy
Of nine patients enrolled at dose levels of 0. 25 /day on day 14. Of these, 13 were able to remain on the higher dose for the duration of treatment, whereas the other two patients required a subsequent decrease back to the 1.75 Â 10 6 IU/m 2 /day dose level because of either anemia or thrombocytopenia. In all, 10 (40%) of the patients, however, were unable to have their dose escalated at day 14 because of side effects, and seven of these patients ultimately were removed from study. /day, four patients received a cell dose of 4.0 Â 10 7 cells/kg (one patient underwent one apheresis, the remaining patients two aphereses); six patients received 8.0 Â 10 7 cells/kg (two patients underwent one apheresis, the remaining four patients two aphereses); 10 patients underwent two lymphaphereses with reinfusion of the full product. Grade I-II toxicities included wheezing (n ¼ 1), mild fever (37.1-38.01C) (n ¼ 4), chills (n ¼ 4), transient decrease in oxygen saturation to 88% during chills (n ¼ 1), and transient decrease of systolic blood pressure to 80-85 mmHg (n ¼ 1). No patient required hospitalization. Two patients were removed from study after the first apheresis (one for facial swelling, one for a bacterial infection). A third patient declined the second apheresis secondary to difficulties with venous access.
Clinical tolerability of IL-2 boluses
All 23 patients received s.c. IL-2 at the MTD of 1.75 Â 10 6 IU/m 2 /day. Three patients made up the first cohort, and all three received 42 days of s.c. IL-2 injections and both planned i.v. IL-2 boluses of 2 Â 10 6 IU/m 2 . Six (50%) of the 12 patients enrolled at the 4 Â 10 6 IU/m 2 dose level received both i.v. boluses. Boluses were not infused because of thrombocytopenia (n ¼ 2), Clostridium difficile infection (n ¼ 1), rash (n ¼ 1), insomnia (n ¼ 1), and neutropenia (n ¼ 1). Of the 12 patients, eight received all 41-42 doses of s.c. IL-2; four patients received p23 days of s.c. IL-2. Grade I toxicities occurring at the IL-2 bolus dose of 4 Â 10 6 IU/m 2 included fever (n ¼ 2), chills (n ¼ 3), and shortness of breath (n ¼ 1). Orthostatic hypotension occurred in two patients-one patient responded to intravenous normal saline, the other had spontaneous resolution of symptoms. All eight patients enrolled at the highest dose of bolus IL-2, 6 Â 10 6 IU/m 2 , received all 42 days of s.c. IL-2 injections and both infusions. Grade II toxicities of fever and chills were noted in all patients during the bolus infusions, and thus this dose was felt to be the MTD of IL-2 boluses. Three patients experienced a X10 mmHg decline in systolic blood pressure and required infusion of normal saline for blood pressure support.
Immune activation after IL-2 therapy
Laboratory tests were performed every 2 weeks to monitor immune activation. There was a significant increase in the total white blood cell count, peaking at day 14 and after each activated cell infusion or IL-2 bolus infusion, analogous to our previously reported findings with post transplant subcutaneous IL-2. 4 The increase in total WBC was primarily because of an increase in the number of circulating lymphocytes and eosinophils; the absolute number of circulating monocytes did not change with IL-2 therapy. The lymphocyte increase included a greater than 10-fold increase in circulating CD56+ bright/CD3À NK cells, which was sustained throughout the IL-2 treatment period. The majority of the NK cells were CD56+ bright/CD16+/CD3À. Less than 2% of CD56+ cells expressed CD3 at any time point. In contrast to the increase in NK cells, the absolute number of T cells remained fairly stable throughout IL-2 administration, consistent with our previous finding. 4 The phenotype of the mononuclear cells was unaltered by ex vivo incubation in IL-2. After 28 days of s.c. IL-2, 4474.6% (n ¼ 20) of PBMNC were CD56+/CD3À NK cells, which did not change after overnight incubation in IL-2 (4374.4%), again in agreement with our previous findings. 4 We tested the lytic function of PBMNC obtained at study entry prior to any s.c. IL-2 administration, pre-and post infusion of IL-2-activated cells, and pre-and post infusion of IL-2 boluses, as well as that of the IL-2-activated NK-cell infusion product against Raji and MCF-7 cells (Figure 1 ). Prior to s.c. IL-2, fresh nonactivated PBMNC had no lytic activity (o5%) against either target. 
Cytokines induced by IL-2
We previously reported that s.c. administration of IL-2 in the post-transplant setting induced the release of soluble IL-2Ra and IFN-g. 4 In contrast, neither IL-12, TNF-a, IL1-b nor IL-6 was significantly augmented compared to baseline levels. In the current study, we determined the circulating cytokine levels of IL-6, IFN-g, TNF-a, and IL1-b in patients at day 0, day 14, and throughout their course of bolus IL-2 infusions. As shown in Figure 2 , IL-2 boluses transiently increased the levels of all four cytokines, although the increase in the level of IL-1b was minimal. Peak levels of IL-6, IFN-g, and TNF-a were noted 2 h after each IL-2 infusion. The peak level for IL1-b occurred 24 h after infusion; a second peak was not noted after the second IL-2 bolus. There was a dose-dependent increase in IL-6 and IFN-g. Patients who received 4-6 Â 10 6 IU/m 2 had a statistically significant greater increase in peak cytokine levels of IL-6 and IFN-g compared to patients who received 2 Â 10 6 IU/m 2 of IL-2 (data not shown).
Clinical outcome following IL-2 immunotherapy: matchedpairs analysis
Patients enrolled at the MTD of s. 6 IU/m 2 /day of s.c. IL-2 were studied before and after starting posttransplant immunotherapy in a 4-h chromium release cytotoxicity assay against Raji (left panel) and MCF-7 (right panel) targets. Patient PBMNC were tested prior to study entry (x, n ¼ 16 for Raji, n ¼ 10 for MCF-7), after 28 days of s.c. IL-2 alone prior to either cell (J) or bolus infusions (&) (n ¼ 18 for Raji, n ¼ 18 for MCF-7) and 24 h after ex vivo IL-2-activated NK cell infusions (, n ¼ 11 for Raji, n ¼ 15 for MCF-7) or IV IL-2 (', n ¼ 9 for both targets). The activity of the first infusion product is also shown (-, n ¼ 13 for Raji, n ¼ 15 for MCF-7). patients with lymphoma, one patient was matched with one control, one with two controls, and 17 with three controls from the registry. For the 18 patients with breast cancer, one patient was matched with one control and 17 patients with three controls from the registry. Patient characteristics are shown in Table 2 . There were either very minimal or no differences between case patients and control patients for all matching characteristics. Disappointingly, improvement in survival or relapse between case and control patients was not detected (Table 3 ). The power to detect a difference in this analysis was low because of the limited patient numbers, but no suggested advantage for the IL-2-based therapy was apparent. The risk of relapse for breast cancer patients treated with IL-2 was greater than for control patients; unmeasured clinical variables not accounted for in the matching criteria may have contributed to the outcome of this analysis.
Discussion
Our previous study suggested that low-dose s.c. IL-2, although safe and easily administered in the outpatient setting, results in submaximal NK lytic function against tumor targets postautologous transplant. Furthermore, based on correlative laboratory studies we hypothesized that additional ex vivo incubation in IL-2 may be used to generate NK cells with enhanced NK lytic function. The goal of the current study was to test this hypothesis by performing a cell dose escalation of IL-2-activated cell therapy with concomitant determination of NK-cell cytotoxicity. We subsequently sought to minimize patient inconvenience as well as the cost associated with ex vivo incubation and reinfusion of activated cells by substitution with bolus IL-2 infusions. After first establishing the MTD of Chiron IL-2, we demonstrated that cytotoxicity was markedly enhanced for cells incubated overnight with IL-2, and from fresh PBMNC obtained the day postinfusion of the IL-2-activated cells against both lymphoma and breast cancer targets. We subsequently confirmed that IL-2 boluses could substitute for ex vivo-activated cells with maintenance of both patient safety as well as the immuneenhancing effects of IL-2.
Toxicities reported in a number of studies with IL-2 and lymphokine-activated killer (LAK) cells have included fever, chills, rash, nausea, dyspnea, thrombocytopenia, and hypotension, 7, 12, 13, 15, 20, 21, 23, 26, 29, 31 similar in spectrum to the toxicities noted in our study. Although direct comparison of the severity of toxicities between studies is problematic, low-dose IL-2 therapies with or without LAK cells appear to be less toxic as high doses of IL-2 and LAK cells have been reported to cause vascular leak syndrome, cardiac arrhythmia, myocardial infarction, and even death. 31 Administration of IL-2 following autologous transplantation may improve immunologic function by inducing cellular changes and indirectly by stimulating the release of cytokines. 7, 10 Normally following autologous transplantation, endogenous NK cells are absent from the blood and appear no earlier than the third week. 7 Both in our prior study and this study, we noted a greater than 10-fold increase in circulating CD56+ bright/CD3À NK cells by day 28 of s.c. IL-2, which was then sustained throughout the IL-2 treatment period. Ex vivo incubation for 16 h in IL-2 did not alter the phenotype of the cells, but greatly enhanced their cytolytic function to a degree analogous to i.v. IL-2 boluses. Other investigators, including Caligiuri et al 8, 9 and Soiffer et al, 10 have noted a similar selective expansion of NK cells in the peripheral blood of patients treated with prolonged uninterrupted continuous infusions of low-dose IL-2, accompanied by enhancement of cytolytic activity. Caligiuri et al 9 treated patients with advanced cancer for 90 days, and demonstrated a gradual, progressive expansion of NK cells with no evidence of plateau effect during the 3 months of therapy. Soiffer et al 10 treated 13 marrow recipients with continuous infusion IL-2 for 90 days. All 13 patients experienced a gradual, incremental (five to 40-fold) increase in NK cell number NK cells constitutively express receptors for monocyte-derived cytokines (monokines) and produce critical cytokines (including IFN-g, TNF-a, and granulocytemacrophage colony-stimulating factor (GM-CSF)) in response to monokine stimulation. 32 In addition to their presumed role in the constitutional symptoms observed with IL-2 administration, 33 theoretically cytokines may be either important mediators or suppressors of IL-2 cell activation. [34] [35] [36] Several studies have attempted to define the nature of the complex cytokine cascade following IL-2 administration. IL-6, granulocyte colony-stimulating factor (G-CSF), and GM-CSF are induced in the blood after administration of IL-2. 37 Bonig et al 38 demonstrated a consistent and early rise of IL-10, IL-5, and GM-CSF during IL-2 therapy. TNF-a, IFN-g, and IL-6 are produced in significant amounts in supernatants of marrow mononuclear cells cultured in IL-2. 39 In the current study, IL-2 boluses transiently increased the levels of IL-6, IFN-g, TNF-a and IL1-b, with a dose-dependent increase in IL-6 and IFN-g.
Several trials with differing eligibility and design have been performed with the aim of evaluating the safety and efficacy of immunotherapy with IL-2 in lymphoma. Benyunes reported a prospective phase II trial of 33 patients with chemosensitive metastatic breast cancer, who underwent transplantation with autologous peripheral blood stem cells cultured in IL-2, followed by post-transplant low-dose IL-2. Compared to historical controls group, the KaplanMeier-estimated 2-year progression-free survival was 35% for IL-2-treated patients, compared with 17% in the control arm (P ¼ 0.73) and the estimated 2-year survival was 78%, compared with 61% in the control arm (P ¼ 0.22).
As no prior study has reported a matched-pairs analysis of postautologous transplantation IL-2 therapy alone, we performed one to assess the possible efficacy of the immune activation we observed. Although there was no trend towards an advantage to IL-2-based immunotherapy, the power to detect a difference in this matched-pairs analysis was low because of limited patient numbers. In order to achieve narrow enough confidence intervals to show statistical significance for the observed estimates of relative risk of death, the study would require approximately 35 lymphoma cases and 25 breast cancer cases with a corresponding increase in the number of controls. Patient heterogeneity may also have obscured a clinical benefit. Thus, a larger and more uniform, prospective randomized study at the MTD of s.c. IL-2-and ex vivo-activated cells or i.v. bolus IL-2 would be needed to clarify the potential for clinical benefit. Enhancement of the potency of IL-2-activated NK cytotoxicity may require the use of more infusions of ex vivo-activated cells or IL-2 boluses, utilization of highly purified NK cells or NK-cell subsets, a combination of IL-2 with tumor-reactive monoclonal antibodies to induce effective antibody-dependent cellular cytotoxicity, 40 combinations of NK-cell immunotherapy with chemotherapy or other cytokines such as IL-12, 41 or augmentation by NK-cell inhibitory receptor blockade. 42 Indeed, as malignant cells may have multiple mechanisms by which they escape from immune control, more than one immunotherapeutic intervention may be necessary to achieve clinical benefit. Further study is clearly needed to IL-2 based immunotherapy after autologous transplantation LJ Burns et al take advantage of the immunotherapeutic potential of IL-2-activated NK cells.
